Posted by Michael Wonder on 01 Sep 2021
FDA approves drug for schizophrenia to be administered at a six month interval
1 September 2021 - The FDA has approved Invega Hafyera (paliperidone palmitate) extended-release injectable suspension to treat schizophrenia in certain adults.
Invega Hafyera, an atypical antipsychotic, is the first long-acting schizophrenia medication to be injected once every six months.
